Regeneron Pharmaceuticals has entered into a $450 million contract with the Office of Biomedical Research and the U.S. Department of Defense to manufacture and supply the Coronavirus drug, REGN-COV2. The drug is currently in Phase II clinical trials as a treatment and Phase III as a COVID-19 prophylactic agent. The agreement will enable the drug to be delivered to the U.S. immediately after FDA approval.
Regeneron Pharmaceuticals has entered into a $450 million contract with the Office of Biomedical Research and the U.S. Department of Defense to manufacture and supply the Coronavirus drug, REGN-COV2. The drug is currently in Phase II clinical trials as a treatment and Phase III as a COVID-19 prophylactic agent. The agreement will enable the drug to be delivered to the U.S. immediately after FDA approval. 
investor.regeneron.com
English (US) 